<SEC-DOCUMENT>0001493152-26-001950.txt : 20260113
<SEC-HEADER>0001493152-26-001950.hdr.sgml : 20260113
<ACCEPTANCE-DATETIME>20260113080010
ACCESSION NUMBER:		0001493152-26-001950
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20260113
FILED AS OF DATE:		20260113
DATE AS OF CHANGE:		20260113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CytoMed Therapeutics Ltd
		CENTRAL INDEX KEY:			0001873093
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			U0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41677
		FILM NUMBER:		26528472

	BUSINESS ADDRESS:	
		STREET 1:		#08-22 ONE COMMONWEALTH
		CITY:			1 COMMONWEALTH LANE
		STATE:			U0
		ZIP:			149544
		BUSINESS PHONE:		603824911

	MAIL ADDRESS:	
		STREET 1:		#08-22 ONE COMMONWEALTH
		CITY:			1 COMMONWEALTH LANE
		STATE:			U0
		ZIP:			149544

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CytoMed Therapeutics Pte. Ltd.
		DATE OF NAME CHANGE:	20210716
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>form6-k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>WASHINGTON,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
6-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNDER
THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the month of January 2026</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Commission
File Number: 001-41677</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>CytoMed
Therapeutics Limited</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1
Commonwealth Lane</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>#08-22</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Singapore
149544</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Address
of Principal Executive Office)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Form
20-F &#9746; Form 40-F &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INFORMATION
CONTAINED IN THIS FORM 6-K REPORT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 13, 2026, CytoMed Therapeutics Limited (the &ldquo;Company&rdquo;) issued a press release announcing its new year update and
inviting shareholders to provide feedback on a proposal to enhance shareholders&rsquo; patient capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibits</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><A HREF="ex99-1.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release dated January 13, 2026, titled: &ldquo;CytoMed Therapeutics&rsquo; new year update and seeks shareholders&rsquo; feedback on proposal to improve shareholder value for their patient capital&rdquo;</FONT></A></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CytoMed
    Therapeutics Limited</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 5%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 45%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; border-bottom: black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    CHOO Chee Kong</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CHOO Chee Kong</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: January 13, 2026</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director and Chairman</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="ex99-1_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CytoMed
Therapeutics&rsquo; new year update and seeks shareholders&rsquo; feedback on proposal to improve shareholder value for their patient
capital</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Singapore,
(January 13, 2026) &ndash;</B>&nbsp;<U>CytoMed Therapeutics Limited</U>&nbsp;(NASDAQ: GDTC) (&ldquo;CytoMed&rdquo; or the &ldquo;Company&rdquo;),
a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable
donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumors, is pleased
to update shareholders as we enter a new exciting year in 2026. As mentioned in previous announcements, CytoMed through new subsidiary
LongevityBank is also diversifying its product pipeline through the process development of clinical-grade cord blood-derived Natural
Killer cells. In so doing, it will enhance access to rare and valuable cord blood as sources for cell-based allogeneic therapies. In
addition to CytoMed&rsquo;s gamma delta T cells, Natural Killer cells also express receptors that recognise stress ligands, allowing
them to be cytotoxic tools to combat a wide variety of solid and hematological cancers.&nbsp; Notably, CytoMed&rsquo;s efforts in development
of Natural Killer cell therapy has recently received support from Enterprise Singapore, a Singapore government agency championing enterprise
development.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
this new year 2026, the Company believes it has enough resources to continue funding its activities for at least a year given our low-cost
infrastructure in Southeast Asia. Besides the usual capital market routes, CytoMed can look to licencing and asset monetisation from
real estate properties which it owns and uses for operation. We are also continuously exploring proposals with sustainable benefits as
we explore with long-term strategic partners including synergistic biotechs and hospitals which can strengthen the business and international
aspects with less dilution. Notably CytoMed was ranked 4 out of 5 points in terms of investment potential in 2025 December&rsquo;s Morning
Star publication. As a matter of full disclosure, our Chairman Peter Choo intends to increase his shareholding in the Company and will
make the relevant announcement as soon as possible.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
announced on December 8, 2025, CytoMed has entered into a Memorandum of Understanding with Universiti Malaya (&ldquo;UM&rdquo;) to establish
a multi-site, first-in-human Phase I clinical trial to investigate the safety and efficacy of CytoMed&rsquo;s patented allogeneic unmodified
Gamma Delta (&gamma;&delta;) T cells (CTM-GDT) (without genetically modifying the cells to express any receptor) for no-option cancer
patients in Malaysia. We target to submit an Investigational New Drug application to the Malaysian authorities before June this year.
This initiative complements CytoMed&rsquo;s ongoing first-in-human Phase I chimeric antigen receptor T (CAR T) cell clinical trial at
National University Hospital Singapore, which uses &gamma;&delta; T cells modified to express a CAR (CTM-N2D) targeting various cancer
types, including advanced colorectal cancer, lymphoma, multiple myeloma, lung cancer, ovarian cancer, hepatocellular carcinoma. To date,
six patients had been treated at two dosage levels in Singapore.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unmodified
gamma delta T cells have been demonstrated in international clinical trials to have potential to kill cancer cells including brain cancers.
CytoMed is co-author in a recent September/ October 2025 publication of a preclinical study, in a research article entitled &ldquo;<I>Donor-Derived
V&gamma;9V&delta;2 T Cells for Acute Myeloid Leukemia: A Promising &ldquo;off-the-shelf&rdquo; Immunotherapy Approach</I>&rdquo;. The
study results from this collaborative research with The University of Texas, MD Anderson Cancer Center (MDACC), are suggesting the great
potential of CytoMed&rsquo;s allogeneic &gamma;&delta; T cell therapy (CTM-GDT) for treating acute myeloid leukemia (AML). This collaboration
with MDACC is under a previously announced research agreement in May 2023. The research article is now publicly and freely online at
<U>Donor-Derived V&gamma;9V&delta;2 T Cells for Acute Myeloid Leukemia: A Promising &ldquo;Off-the-Shelf&rdquo; Immunotherapy Approach.</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chairman
Peter Choo commented &ldquo; Our allogeneic CAR T cells are on clinical trial and many no-option cancer patients with unmet needs or
failed conventional cancer treatments have approached us. Healthcare cost in the West is prohibitive and is the main reason why
international medical tourism is booming in Southeast Asia where costs are substantially lower than in the West. We believe we can
manufacture clinical grade therapeutics in Southeast Asia at low cost&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
line with above, the Company intends to seek feedback and opinion from shareholders on a novel scheme under which a shareholder can use
his shareholding to get access to the Company&rsquo;s donor-derived allogeneic unmodified gamma delta T cells subject to the doctor&rsquo;s
approval and home country regulations. Shareholders are encouraged to contact the Company for further information and share their ideas.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="border-bottom: Black 1pt solid; margin-bottom: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
CytoMed Therapeutics Limited (CytoMed)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Incorporated
in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore&rsquo;s leading research and development
agency in the public sector. CytoMed is a clinical stage biopharmaceutical company focused on harnessing its licensed proprietary technologies,
namely gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell, to create novel cell-based allogeneic immunotherapies for
the treatment of various human cancers. The development of novel technologies has been inspired by the clinical success of existing CAR-T
therapies in treating haematological malignancies, as well as the current clinical limitations and commercial challenges in extrapolating
the CAR-T principle into the treatment of solid tumours. For more information, please visit <U>www.cytomed.sg</U> and follow us on Twitter
(&ldquo;X&rdquo;) <U>@CytomedSG</U>, on <U>LinkedIn</U>, and <U>Facebook</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking
statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions
and other statements that are other than statements of historical facts. When the Company uses words such as &ldquo;may, &ldquo;will,
&ldquo;intend,&rdquo; &ldquo;should,&rdquo; &ldquo;believe,&rdquo; &ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;project,&rdquo;
&ldquo;estimate&rdquo; or similar expressions that do not relate solely to historical matters, it is making forward-looking statements.
Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results
to differ materially from the Company&rsquo;s expectations discussed in the forward-looking statements. These statements are subject
to uncertainties and risks including, but not limited to, the following: the Company&rsquo;s plans to develop and commercialize its product
candidates; the initiation, timing, progress and results of the Company&rsquo;s current and future pre-clinical studies and clinical
trials and the Company&rsquo;s R&amp;D programs; the Company&rsquo;s estimates regarding expenses, future revenue, capital requirements
and needs for additional financing; the Company&rsquo;s ability to successfully acquire or obtain licenses for additional product candidates
on reasonable terms; the Company&rsquo;s ability to establish and maintain collaborations and/or obtain additional funding and assumptions
underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons,
among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional
factors are discussed in the Company&rsquo;s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes
no obligation to publicly revise these forward&ndash;looking statements to reflect events or circumstances that arise after the date
hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale
of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification
under the securities laws of any such jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contact
:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CytoMed
Therapeutics Limited</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">enquiry@cytomed.sg</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Attention
: Evelyn Tan, Chief Corporate Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !P / # 2(  A$! Q$!_\0
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MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBDR>O
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M;$6IT]K*W^P&)[86GEPB 0K\@MA 8_)$)0^6(Q'EX\ $XQ7RQ\4/V5OAM?\
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M93H^OZ5=[%M9;:;[/]D\TH)1NV^G?\%A/$.M>-?B[\!OA3I5I;W)GT%-1TJ
M(99Y]5\5:T-'2!FB8@11QP02\9)7?)&'P#7'PAX0Y=1\2.!L'F69Y=G_  /Q
M'E^8<1TLR@ZM"AC,JP="K*O+$PG!3PTZ%>$:=2GS)*49N\5%<WK<3>*F.Q'
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M^W5JLL[S"4+WO+"NM+ZMO:5U2M=V:U5MF6">H'7C]?\   FJ][,MI;R32H7
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M[Y!!M@3$8E8JV(5.DU)^['WDFFXW:YK<UEK+1?$K176[W[.(N+N+\ES?"8#
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M6K-KKO@!^TO\*_@=^Q3HWQ%LO"WBBPTA_&WB#PWH_A.?57\1^(M8\5:AK=[
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M+89@5.TY!P?QL;7_ -NH;0W_  4V_8G0R.L*8\$Z>S&61@D:*IUX%G9W550
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MAI\"]7\+R>);K1](MH)M-\57MM<3+<V%M<V]Q;FZ$MP-0B"3&TBW[5 /CO\
M89M?V<O$?PN:U\0?\$VO%?[7/Q&T#Q'K.J7_ (^\(^,;..XLM%>\%UX=TZXT
M877VNVFTF.$V[2FV:*60>8)W)(']//Q;^#UA^W3^P[-\,/'>E>)_V<[/XJ>$
M/#[7>BZF-&UGQ3\.CH]];36.EWL>HQ1Z+<7T(TZ"$FX98621&#&7D_D)\=_"
M?P5\3:GX:^(_[+?[/_[:?[)WQO\ !TGAVUT;QE\//@MK>F:#J6A:3-''<Z=X
MIT&WFA@UAWL!(L5S<REYIV(O#,CG/[%Z3HW@G]O/]F'6/AS\4O"GQL\,>&=3
M&C^%_$S>-](N_ACX^\0WOADV-V_B"VM]LS6=GJ>HVQN2]MOBE#O&I*L<@'YG
M>/?V4/VKOA[XAUC0/@_\#/\ @FOXK^"/@K2='TSP/XG^*7AW0U^(>I:/H^@V
M<%_K7B_[)X7N8?[8N[V"\N[F*UN)(7W!(9&!%?(/[)7Q$_:!_:M\>V.@Z%^Q
M1^QE)\&K;Q/)X<^(GQ1TSX6^&M$T&RT&.22TU6^\+ZIJ,-K-JUY9K(US9BUL
M)I!,\*S&.-C7U5^UU^P%_P $Y?V0_!.E>,O'/P]_:2\2V?B2[U#0=-NO VN>
M(?%J:9K:::UW82Z_#86N^SM+N4JD%RZ&,RQLI50V3QG_  3E_P""57P"^.7[
M+?ASXD?'OP;\3M&\::_XC\3&SLH?$^J>$PWAJ*\A_L*\DT00#[/<7%LH65KC
M<[A%P%.Y: /V@_8F_95\)?L>?!^7X.>#O&%UXTT,^,?%'B^/5KRQT;3I[>7Q
M)J+7CZ9]GT+%DMK9%EBM&(64Q*/, 8$#[) P /3UYKYK_9E_96^%?[)W@6Y^
M'GPBB\0V_AR^UBYURY_X237)]>U%KZY.7 O)XT/V?^$1A<   'J:^E , #GC
MUY- #67=@C&1T)Z#.,Y'?./U]13/+;'5>@&<'..??'.3[^F*FHHWNN^GWB:O
M;5JVOSZ&7-:B6.56"2*5<%&0,K*P(9'!5MR."=ZMD,0.!C%?DQ^V'_P2[\ _
M'"\U'QW\)[K3?AI\29K>,W%O#:J/"7B*X5VE=[ZPMPLEK>7!9HVO+<]=KNGR
MDU^O3#*L!W4C\QBHECYRR+@#CH?FR,'IQCGFOHN%>+>(N"\UP^<<-YIB,MQF
M'DG[DY2I58II\E:DYJG5AHURS@VE)\LH-W?S7%'".0\9997RGB# 4<7AJWO<
MRA&%>G42:C.%91<U9V;2=I-:^7\.7QB_9V^-/P"U=M+^*O@+6-!A@EG%OXD@
MM9M0\-72Q847%IK-G'+;QK+&0RB\,7DHVPL&R:X?P7\1?'OP]O8]1\!>-O$G
MA>6.2*3&B:W=V]I*8C^X$MLDSVTL29+(I0HQR2#7]T.N>&=$\2V-UI7B/2-+
MUK3KR,Q3V.IVL%[;2QL#N62"X22%XR,9&PGU!ZU\$?$G_@EQ^R-\1;V74#X
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2:JBKSP H  JY10 4444 ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
